Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND -0.50%11 Net Margin % is -3,009.38% as of Mar. 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Vyome Holdings ranks worse than 91.4% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Vyome Holdings's Net Income for the
three
months ended in Mar. 2026 was $-0.96 Mil. Vyome Holdings's Revenue for the
three
months ended in Mar. 2026 was $0.03 Mil. Therefore, Vyome Holdings's net margin for the quarter that ended in Mar. 2026 was -3,009.38%.
The historical rank and industry rank for Vyome Holdings's Net Margin % or its related term are showing as below:
HIND'
s Net Margin % Range Over the Past 10 Years
Min: -7098.05 Med: -445.36 Max: -173.08
Current: -7098.05
HIND's Net Margin % is ranked worse than 91.4% of 942
companies
in the Biotechnology industry
Industry Median: -89.635
vs HIND: -7098.05
Vyome Holdings (NAS:HIND) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vyome Holdings Net Margin % Related Terms
Vyome Holdings Net Margin % Historical Data
* Premium members only.
The historical data trend for Vyome Holdings's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vyome Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vyome Holdings (HIND) has a Net Margin % of -3,009.38% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Vyome Holdings and its competitors. According to the industry distribution chart, Vyome Holdings ranks #861 out of 942 companies in the Biotechnology industry, placing it in the top 91.4%.
Is Vyome Holdings' Net Margin % too high?
Vyome Holdings' current Net Margin % is -3,009.38%. Based on the distribution chart, Vyome Holdings ranks #861 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' Net Margin % compare to CTXR and MBRX?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #861 out of 942 companies for Net Margin %. This places Vyome Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vyome Holdings and its competitors. Vyome Holdings's current Net Margin % is -3,009.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current Net Margin % of -3,009.38%. The current Net Margin % is -3,009.38%. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vyome Holdings (HIND), the current Net Margin % is -3,009.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
